FABP3 and congestive heart failure: An increasing body of evidence supports the notion that both FABP3 and FABP4 serum concentrations can predict both all-cause [36,37,38,39,40,41,42] and CV mortality [40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58]; however, the potential role of these FABPs as predictive biomarkers for the mortality risk among subjects with T2D and chronic HF (CHF) has not been explored yet.